- Home
- STRO vs ZURA Comparison
STRO vs ZURA Comparison
Compare STRO & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- ZURA
- Stock Information
- Founded
- STRO 2003
- ZURA 2022
- Country
- STRO United States
- ZURA United States
- Employees
- STRO N/A
- ZURA N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STRO Health Care
- ZURA Health Care
- Exchange
- STRO Nasdaq
- ZURA Nasdaq
- Market Cap
- STRO 77.7M
- ZURA 69.9M
- IPO Year
- STRO 2018
- ZURA N/A
- Fundamental
- Price
- STRO $0.76
- ZURA $1.31
- Analyst Decision
- STRO Hold
- ZURA Buy
- Analyst Count
- STRO 7
- ZURA 7
- Target Price
- STRO $3.97
- ZURA $14.33
- AVG Volume (30 Days)
- STRO 1.2M
- ZURA 712.2K
- Earning Date
- STRO 08-12-2025
- ZURA 08-08-2025
- Dividend Yield
- STRO N/A
- ZURA N/A
- EPS Growth
- STRO N/A
- ZURA N/A
- EPS
- STRO N/A
- ZURA N/A
- Revenue
- STRO $66,434,000.00
- ZURA N/A
- Revenue This Year
- STRO N/A
- ZURA N/A
- Revenue Next Year
- STRO N/A
- ZURA N/A
- P/E Ratio
- STRO N/A
- ZURA N/A
- Revenue Growth
- STRO N/A
- ZURA N/A
- 52 Week Low
- STRO $0.52
- ZURA $0.97
- 52 Week High
- STRO $5.17
- ZURA $5.07
- Technical
- Relative Strength Index (RSI)
- STRO 49.28
- ZURA 59.63
- Support Level
- STRO $0.73
- ZURA $1.00
- Resistance Level
- STRO $0.83
- ZURA $1.45
- Average True Range (ATR)
- STRO 0.06
- ZURA 0.10
- MACD
- STRO 0.01
- ZURA 0.03
- Stochastic Oscillator
- STRO 61.90
- ZURA 68.89
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.